COMP <GO>
AVTR vs ABBV // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Avantor Inc. (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: AVTR 3
— ABBV 11
▲ OPTIONS IMPLIED MOVE & PUT/CALL SKEW LEADER: AVTR
LAST: $16.05 (-3.78%) • MKT CAP: $11.30B
options-implied-move
6.90%
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
options-implied-move
7.40%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AVTR VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AVTR | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 32.70% | 70.20% | -37.50 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -2.10% | 29.00% | -31.10 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 4.38% | 3.47% | +0.91 | AVTR | /fcf-yield <GO> |
| Operating Margin | -3.80% | 24.60% | -28.40 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -8.10% | 6.90% | -15.00 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | -3.40% | 8.60% | -12.00 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.88 | 5.33 | -3.45 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | 6.90% | 7.40% | -0.50 | AVTR | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 49.1 | 72.8 | -23.68 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.01 | 1.15 | -0.14 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 31.0x | 113.1x | -82.10 | AVTR | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $11.30B | $513.86B | -$502.56B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AVTR REV | ABBV REV | AVTR GROSS % | ABBV GROSS % | AVTR FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $6.55B | $61.16B | 32.7% | 70.2% | $495.0M | $17.82B |
| FY 2024 | $6.78B | $56.33B | 33.6% | 70.0% | $692.0M | $17.83B |
| FY 2023 | $6.97B | $54.32B | 44.0% | 44.0% | $556.5M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AVTR // BETA 1.01
ABBV // BETA 1.15